Update on the treatment of narcolepsy: clinical efficacy of pitolisant
Michael W Calik1,2 1Department of Biobehavioral Health Science, 2Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States Abstract: Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytim...
Guardado en:
Autor principal: | Calik MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/08af899450d7422ebde356d903c212e4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra JT, et al.
Publicado: (2020) -
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report
por: Pellitteri G, et al.
Publicado: (2020) -
New developments in the management of narcolepsy
por: Abad VC, et al.
Publicado: (2017) -
Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns
por: Barker EC, et al.
Publicado: (2020) -
The Association Between Asthma and Narcolepsy: A Nationwide Case-Control Study in Taiwan
por: Chen TY, et al.
Publicado: (2021)